Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 2/20 | 0.51 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.48 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.44 |
| ▸ | P2RY6 | Q15077 | 9/20 | 0.44 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.42 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.41 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.41 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.41 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7553293 | 1.00 | TYMP (0.51) | TYMPP2RY14P2RY2P2RY6P2RY4 | |
| SCHEMBL6930000 | 0.94 | TYMP (0.49) | TYMPP2RY14P2RY2P2RY6P2RY4 | |
| SCHEMBL6930638 | 0.94 | TYMP (0.48) | TYMPP2RY14P2RY2P2RY6P2RY4 | |
| SCHEMBL6930639 | 0.94 | TYMP (0.48) | TYMPP2RY14P2RY2P2RY6P2RY4 | |
| SCHEMBL31093241 | 0.94 | TYMP (0.48) | TYMPP2RY14P2RY2P2RY6P2RY4 | |
| SCHEMBL7913274 | 0.94 | TYMP (0.48) | TYMPP2RY14P2RY2P2RY6P2RY4 | |
| SCHEMBL6831397 | 0.93 | TYMP (0.51) | TYMPP2RY14P2RY2P2RY6P2RY4 | |
| SCHEMBL6831398 | 0.93 | TYMP (0.51) | TYMPP2RY14P2RY2P2RY6P2RY4 | |
| SCHEMBL3721728 | 0.92 | TYMP (0.53) | TYMPP2RY14P2RY2P2RY6P2RY4 | |
| SCHEMBL19549038 | 0.92 | TYMP (0.53) | TYMPP2RY14P2RY2P2RY6P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090198047-A1 | 2'-Modified Oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| US-20080032945-A1 | 2'-MODIFIED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2008-02-07 | — | — | US | disclosed |
| US-7138517-B2 | Sugar modified oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2006-11-21 | — | — | US | disclosed |
| EP-0651759-B1 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF | ISIS PHARMACEUTICALS INC (US) | 2003-12-10 | — | — | EP | disclosed |
| US-20030187240-A1 | 2' -modified oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2003-10-02 | — | — | US | disclosed |
| US-6531584-B1 | Nuclease resistant oligonucleotide analogs; DNA or RNA modulation; diagnosis, thearpy of viral diseases | ISIS PHARMACEUTICALS, INC. | 2003-03-11 | — | — | US | disclosed |
| US-20030004325-A1 | Sugar modified oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2003-01-02 | — | — | US | disclosed |
| EP-1223173-A2 | Novel 2'-O-alkyl nucleosides and phosphoramidites processes for the preparation and uses thereof | ISIS PHARMACEUTICALS, INC. (US) | 2002-07-17 | — | — | EP | disclosed |
| US-6399754-B1 | CONTAINING SULFOPHOSPHATE GROUP | ISIS PHARMACEUTICALS, INC. | 2002-06-04 | — | — | US | disclosed |
| US-6242592-B1 | Process for the preparation of 2′-O-alkyl-guanosine, cytidine, and uridine phosphoramidites | ISIS PHARMACEUTICALS, INC. | 2001-06-05 | — | — | US | disclosed |
| US-6090932-A | Method of preparation of known and novel 2'-modified nucleosides by intramolecular nucleophilic displacement | PROLIGO LLC (US) | 2000-07-18 | — | — | US | disclosed |
| US-6005087-A | NUCLEASE RESISTANT OLIGONUCLEOTIDES WHICH ARE USEFUL AS THERAPEUTICS, DIAGNOSTICS, AND RESEARCH REAGENTS FOR VARIOUS VIRAL DISEASES | ISIS PHARMACEUTICALS, INC. (US) | 1999-12-21 | — | — | US | disclosed |
| US-5914396-A | 2'-O-modified nucleosides and phosphoramidites | ISIS PHARMACEUTICALS, INC. (US) | 1999-06-22 | — | — | US | disclosed |
| US-5872232-A | 2'-O-modified oligonucleotides | ISIS PHARMACEUTICALS INC. (US) | 1999-02-16 | — | — | US | disclosed |
| US-5859221-A | HYBRID DNA, RNA; NUCLEASE RESISTANT | ISIS PHARMACEUTICALS, INC. (US) | 1999-01-12 | — | — | US | disclosed |
| US-5856466-A | Process for the preparation of 2'-O-alkyl purine phosphoramidites | ISIS PHARMACEUTICALS, INC. (US) | 1999-01-05 | — | — | US | disclosed |
| US-5646265-A | Process for the preparation of 2'-O-alkyl purine phosphoramidites | ISIS PHARMCEUTICALS, INC. (US) | 1997-07-08 | — | — | US | disclosed |
| EP-0651759-A4 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF. | ISIS PHARMACEUTICALS INC (US) | 1995-10-25 | — | — | EP | disclosed |
| EP-0651759-A1 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 1995-05-10 | — | — | EP | disclosed |
| WO-1994002501-A1 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 1994-02-03 | — | — | WO | disclosed |